CN Patent

CN110603255B — Jak抑制剂化合物的结晶型式

Assigned to Theravance Biopharma R&D IP LLC · Expires 2023-02-10 · 3y expired

What this patent protects

本发明提供5‑乙基‑2‑氟‑4‑(3‑(5‑(1‑甲基哌啶‑4‑基)‑4,5,6,7‑四氢‑1H‑咪唑并[4,5‑c]吡啶‑2‑基)‑1H‑吲唑‑6‑基)苯酚的草酸盐和琥珀酸盐结晶水合物。本发明还提供包含所述结晶水合物的药物组合物、使用所述结晶水合物治疗呼吸道疾病和其它疾病的方法以及可用于制备所述结晶草酸盐和琥珀酸盐水合物的方法。

USPTO Abstract

本发明提供5‑乙基‑2‑氟‑4‑(3‑(5‑(1‑甲基哌啶‑4‑基)‑4,5,6,7‑四氢‑1H‑咪唑并[4,5‑c]吡啶‑2‑基)‑1H‑吲唑‑6‑基)苯酚的草酸盐和琥珀酸盐结晶水合物。本发明还提供包含所述结晶水合物的药物组合物、使用所述结晶水合物治疗呼吸道疾病和其它疾病的方法以及可用于制备所述结晶草酸盐和琥珀酸盐水合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN110603255B
Jurisdiction
CN
Classification
—
Expires
2023-02-10
Drug substance claim
No
Drug product claim
No
Assignee
Theravance Biopharma R&D IP LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.